228 related articles for article (PubMed ID: 26566105)
21. Should the Dose of Antiplatelet Drugs Be Adjusted for Body Weight? The Example of Vorapaxar.
Serebruany VL; Fortmann SD; Kim MH
Cardiology; 2016; 133(2):69-72. PubMed ID: 26488178
[TBL] [Abstract][Full Text] [Related]
22. Impact of selective platelet inhibition in reducing cardiovascular risk - role of vorapaxar.
Cheng JW
Vasc Health Risk Manag; 2016; 12():263-8. PubMed ID: 27366081
[TBL] [Abstract][Full Text] [Related]
23. Vorapaxar in patients with coronary artery bypass grafting: Findings from the TRA 2°P-TIMI 50 trial.
Kosova EC; Bonaca MP; Dellborg M; He P; Morais J; Oude Ophuis T; Scirica BM; Tendera M; Theroux P; Braunwald E; Morrow DA
Eur Heart J Acute Cardiovasc Care; 2017 Mar; 6(2):164-172. PubMed ID: 27075924
[TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetic drug evaluation of vorapaxar for secondary prevention after acute coronary syndrome.
Perez-Rivera JA; Monedero-Campo J; Cieza-Borrella C; Ruiz-Perez P
Expert Opin Drug Metab Toxicol; 2017 Mar; 13(3):339-350. PubMed ID: 28135897
[TBL] [Abstract][Full Text] [Related]
25. Effect of age on efficacy and safety of vorapaxar in patients with non-ST-segment elevation acute coronary syndrome: Insights from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) trial.
Armaganijan LV; Alexander KP; Huang Z; Tricoci P; Held C; Van de Werf F; Armstrong PW; Aylward PE; White HD; Moliterno DJ; Wallentin L; Chen E; Harrington RA; Strony J; Mahaffey KW; Lopes RD
Am Heart J; 2016 Aug; 178():176-84. PubMed ID: 27502866
[TBL] [Abstract][Full Text] [Related]
26. Vorapaxar and diplopia: Possible off-target PAR-receptor mismodulation.
Serebruany VL; Fortmann SD; Rao SV; Tanguay JF; Lordkipanidze M; Hanley DF; Can M; Kim MH; Marciniak TA
Thromb Haemost; 2016 May; 115(5):905-10. PubMed ID: 26887783
[TBL] [Abstract][Full Text] [Related]
27. A State Transition Model for Health Outcomes Associated with Vorapaxar Treatment as an Add-on to Standard Care Antiplatelet Therapy in the Prevention of Thrombotic Events for Patients with a Recent Myocardial Infarction.
Whalen JD; Davies G; Du M; Oguz M; Bash LD; Ozer-Stillman I
Am J Cardiovasc Drugs; 2016 Aug; 16(4):285-295. PubMed ID: 27262432
[TBL] [Abstract][Full Text] [Related]
28. Safety of the novel protease-activated receptor-1 antagonist vorapaxar in Japanese patients with a history of ischemic stroke.
Shinohara Y; Goto S; Doi M; Jensen P
J Stroke Cerebrovasc Dis; 2012 May; 21(4):318-24. PubMed ID: 20947374
[TBL] [Abstract][Full Text] [Related]
29. Vorapaxar with or without clopidogrel after non-ST-segment elevation acute coronary syndromes: results from the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome trial.
Tricoci P; Lokhnygina Y; Huang Z; Van de Werf F; Cornel JH; Chen E; Wallentin L; Held C; Aylward PE; Moliterno DJ; Jennings LK; White HD; Armstrong PW; Harrington RA; Strony J; Mahaffey KW
Am Heart J; 2014 Dec; 168(6):869-77.e1. PubMed ID: 25458650
[TBL] [Abstract][Full Text] [Related]
30. Acute Limb Ischemia and Outcomes With Vorapaxar in Patients With Peripheral Artery Disease: Results From the Trial to Assess the Effects of Vorapaxar in Preventing Heart Attack and Stroke in Patients With Atherosclerosis-Thrombolysis in Myocardial Infarction 50 (TRA2°P-TIMI 50).
Bonaca MP; Gutierrez JA; Creager MA; Scirica BM; Olin J; Murphy SA; Braunwald E; Morrow DA
Circulation; 2016 Mar; 133(10):997-1005. PubMed ID: 26826179
[TBL] [Abstract][Full Text] [Related]
31. Clopidogrel, prasugrel, ticagrelor or vorapaxar in patients with renal impairment: do we have a winner?
Serebruany VL; Tomek A; Pokov AN; Kim MH
Expert Rev Cardiovasc Ther; 2015 Dec; 13(12):1333-44. PubMed ID: 26513059
[TBL] [Abstract][Full Text] [Related]
32. Vorapaxar: The Current Role and Future Directions of a Novel Protease-Activated Receptor Antagonist for Risk Reduction in Atherosclerotic Disease.
Gryka RJ; Buckley LF; Anderson SM
Drugs R D; 2017 Mar; 17(1):65-72. PubMed ID: 28063023
[TBL] [Abstract][Full Text] [Related]
33. Thrombin-receptor antagonist vorapaxar in acute coronary syndromes.
Tricoci P; Huang Z; Held C; Moliterno DJ; Armstrong PW; Van de Werf F; White HD; Aylward PE; Wallentin L; Chen E; Lokhnygina Y; Pei J; Leonardi S; Rorick TL; Kilian AM; Jennings LH; Ambrosio G; Bode C; Cequier A; Cornel JH; Diaz R; Erkan A; Huber K; Hudson MP; Jiang L; Jukema JW; Lewis BS; Lincoff AM; Montalescot G; Nicolau JC; Ogawa H; Pfisterer M; Prieto JC; Ruzyllo W; Sinnaeve PR; Storey RF; Valgimigli M; Whellan DJ; Widimsky P; Strony J; Harrington RA; Mahaffey KW;
N Engl J Med; 2012 Jan; 366(1):20-33. PubMed ID: 22077816
[TBL] [Abstract][Full Text] [Related]
34. Vorapaxar: emerging evidence and clinical questions in a new era of PAR-1 inhibition.
Ungar L; Rodriguez F; Mahaffey KW
Coron Artery Dis; 2016 Nov; 27(7):604-15. PubMed ID: 27398626
[TBL] [Abstract][Full Text] [Related]
35. The FDA review on data quality and conduct in vorapaxar trials: Much better than in PLATO, but still not perfect.
Serebruany VL; Choi SY; Kim MH
Int J Cardiol; 2016 Feb; 205():13-16. PubMed ID: 26709134
[TBL] [Abstract][Full Text] [Related]
36. New ischemic stroke and outcomes with vorapaxar versus placebo: results from the TRA 2 °P-TIMI 50 trial.
Bonaca MP; Scirica BM; Braunwald E; Wiviott SD; Goto S; Nilsen DW; Bonarjee V; Murphy SA; Morrow DA
J Am Coll Cardiol; 2014 Dec; 64(22):2318-26. PubMed ID: 25465417
[TBL] [Abstract][Full Text] [Related]
37. Vorapaxar, a platelet thrombin-receptor antagonist, in medically managed patients with non-ST-segment elevation acute coronary syndrome: results from the TRACER trial.
Held C; Tricoci P; Huang Z; Van de Werf F; White HD; Armstrong PW; Ambrosio G; Aylward PE; Moliterno DJ; Wallentin L; Chen E; Erkan A; Jiang L; Strony J; Harrington RA; Mahaffey KW
Eur Heart J Acute Cardiovasc Care; 2014 Sep; 3(3):246-56. PubMed ID: 24627331
[TBL] [Abstract][Full Text] [Related]
38. Improving Outcomes in Cardiovascular Diseases: A Review on Vorapaxar.
Chaudhary R; Mohananey A; Sharma SP; Singh S; Singh A; Kondur A
Cardiol Rev; 2022 Sep-Oct 01; 30(5):241-246. PubMed ID: 33758122
[TBL] [Abstract][Full Text] [Related]
39. Vorapaxar expands antiplatelet options. Which patients may benefit from thrombin receptor antagonism?
Duerschmied D; Bode C
Hamostaseologie; 2012; 32(3):221-7. PubMed ID: 22777302
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and Safety of Vorapaxar With and Without a Thienopyridine for Secondary Prevention in Patients With Previous Myocardial Infarction and No History of Stroke or Transient Ischemic Attack: Results from TRA 2°P-TIMI 50.
Bohula EA; Aylward PE; Bonaca MP; Corbalan RL; Kiss RG; Murphy SA; Scirica BM; White H; Braunwald E; Morrow DA
Circulation; 2015 Nov; 132(20):1871-9. PubMed ID: 26338971
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
